Navigation Links
Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
Date:8/21/2008

SAN FRANCISCO, Aug. 21 /PRNewswire-FirstCall/ -- Medizone International, Inc. (Pink Sheets: MZEI) announces the appointment of Michael E. Shannon, M.A., M.Sc., M.D. to its Board of Directors. Dr. Shannon received his medical degree from Queen's University in Canada, which included advanced training in surgery and sports medicine. He also holds post-graduate degrees in neurochemistry and physiology. He has been actively engaged in applied medical research within these areas for over 27 years. He served in the Canadian Forces for 31 years retiring at the rank of Commodore (Brigadier General equivalent) as Deputy Surgeon General for Canada. During the first Gulf War, Dr. Shannon served as the senior medical liaison officer for all of the Canadian forces. In 1996 he assumed responsibilities within Health Canada for re-organizing the Canadian blood system. Working with both the provincial and federal governments, he oversaw the development of a new corporate entity dedicated exclusively to the management of blood services in Canada. He was then appointed Director General for the Laboratory Centre for Disease Control, a position he held for three years. In December 2000, Dr. Shannon left the Canadian federal government to pursue a new career in industry. In that capacity he simultaneously directed a phase III clinical trial in Canada, the United States and Great Britain for an artificial blood substitute product. Following completion of that work he was asked to accept a special assignment with the Canadian Federal Government Auditor General's office. His assignment was to conduct a cost benefit analysis of all government sponsored pharmacare programs and make recommendations directly to the Parliament of Canada. His assignment and presentation to Parliament on that project was completed in November 2004. Dr. Shannon recently worked on a special project assignment as Senior Medical Advisor to the Canadian Public Health Agency. His assignment was to review and help rebuild the Canadian Public Health Agency's Emergency Medical Response Capacity. His work in that regard with the Canadian government was completed the end of July this year.

Internationally respected for his expertise, Dr. Shannon has been actively engaged in medical bio-oxidative (O3 based), research since 1987 and was directly responsible for the first human clinical trial to have ever been approved in North America which examined the efficacy of O3 delivered via autohemotherapy in the treatment of AIDS. He was also responsible for several primate studies utilizing O3 involving scientists from various departments within the Canadian Federal Government, as well as senior investigators from Medizone International and Cornell University.

Medizone's Chairman and CEO, Edwin Marshall commented; "On behalf of the members of the board and all of the Company's shareholders, we welcome Dr. Shannon to our Board of Directors. The wisdom and expertise Dr. Shannon brings to Medizone is unparalleled in the history of our company. I consider him a remarkable man and feel honored to be able to refer to him as a professional associate. This appointment signals an immense step forward in the reorganization of Medizone International.

Medizone International, Inc., is a research and development stage company engaged in the development of patented and unpatented technologies and protocols for O3 based bio-oxidative treatment of diseases caused by lipid enveloped viruses, including Acquired Immune Deficiency Syndrome (AIDS), Hepatitis B & C, and Herpes, the decontamination of blood, blood products and veterinarian serum products, and the treatment of external pathogenic conditions.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.


'/>"/>
SOURCE Medizone International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
2. BioEnergy International, LLC Acquires Assets of OmniGene Bioproducts, Inc.
3. Cryo-Cell International, Inc. Reports Second Quarter 2008 Results
4. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
5. Chindex International, Inc. Quantifies Fourth Quarter Charges
6. Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results
7. LifeStem International, Inc. Announces Increased Revenues, Decreased Operating Expenses
8. MINRAD International, Inc. to Discuss 2008 First Quarter Financial Results on Tuesday, May 13, 2008
9. MINRAD International, Inc. Announces $40.0 Million Private Placement
10. China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network
11. Cryo-Cell International, Inc. Reports First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ACEA Biosciences, Inc. announced ... I/II clinical trials for AC0010 at the World Conference on Lung Cancer 2016, taking ... update on the phase I/II clinical trials for AC0010 in patients with advanced non-small ...
(Date:12/2/2016)... ... December 01, 2016 , ... The Conference Forum has announced ... days and will take place on February 1-3, 2017 at the Roosevelt Hotel in ... (NCI), the program provides a unique 360-degree approach, which addresses the most up-to-date information ...
(Date:12/2/2016)... ... 2016 , ... Robots will storm the Prudential Center in Boston, MA during ... which is held on the United Nations International Day of Persons with Disabilities, will ... workplace. Suitable Technologies is partnering with NTI to showcase how technology can help individuals ...
(Date:11/30/2016)... ... November 30, 2016 , ... BEI Kimco, a brand of ... flexure design that ensures high alignment accuracy by preventing unwanted shaft rotation. The ... where extreme precision is required, such as in medical equipment, laboratory instrumentation, clean ...
Breaking Biology Technology:
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
(Date:11/21/2016)...   Neurotechnology , a provider of high-precision ... that the MegaMatcher On Card fingerprint matching algorithm ... NIST Minutiae Interoperability Exchange (MINEX) III ... of the evaluation protocol. The ... fingerprint templates used to establish compliance of template ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
Breaking Biology News(10 mins):